ClinicalTrials.gg
TerminatedNCT02171546Updated Jun 24, 2014

Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers

A Phase 1 interventional study of Dabigatran etexilate capsules and Quinidine sulfate tablets in Healthy, sponsored by Boehringer Ingelheim. Terminated. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Part 1: To investigate the effect of quinidine, a P-glycoprotein (P-gp) probe inhibitor on the bioavailability of dabigatran etexilate,

Part 2: To determine the effect of quinidine on the bioavailability of fexofenadine, a probe substrate for P-gp

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead , clinical laboratory tests ;
  2. Age ≥18 and Age ≤55 years;
  3. (BMI) ≥18.5 and BMI \<30 kg/m2;
  4. Signed and dated written prior to admission to the study in accordance with GCP and the local legislation;
  5. If female of , not be pregnant or breast feeding, nor plan to become pregnant for the duration of the study and for 2 months after receiving the last dose of study drug, and have a negative serum pregnancy test within 14 days of treatment, and prior to dosing;
  6. Females of child-bearing potential willing to use adequate , defined as the use of hormonal (oral, injectable or implantable) or barrier method contraceptives, intrauterine device and agree to use the same method of contraception for at least 2 months after drug administration. Women who have undergone a total hysterectomy, have a history of bilateral tubal ligation or are at least 2 years are not considered to be of child-bearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Any finding of the medical examination (including BP, PR and ) deviating from normal and of clinical relevance;
  2. Any evidence of a concomitant disease;
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders;
  4. Surgery of the gastrointestinal tract (except appendectomy);
  5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders;
  6. History of relevant orthostatic hypotension, fainting spells or blackouts;
  7. Chronic or relevant acute infections;
  8. History of relevant allergy/ (including allergy to drug or its );
  9. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial;
  10. Use of drugs which might reasonably influence the results of the trial or that prolong the /QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial;
  11. Participation in another trial with an drug within two months prior to administration or during the trial;
  12. Smoker (>10 cigarettes or >3 cigars or >3 pipes/day);
  13. Inability to refrain from smoking on trial days;
  14. Alcohol abuse (more than 60 g/day);
  15. Drug abuse;
  16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial);
  17. Excessive physical activities (within one week prior to administration or during the trial);
  18. Any laboratory value outside the reference range that is of clinical relevance;
  19. Inability to comply with dietary regimen of trial site;
  20. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms);
  21. A history of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome);
  22. Taking drugs which are known P-gp inhibitors or inducers (verapamil, phenothiazine antipsychotics, erythromycin, antifungal drugs or St. John´s Wort) within the last 4 weeks before screening;
  23. Chronic use of oral containing ethinyl estradiol as the only method of contraception.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    Dabigatran etexilate capsules

    Drug: Dabigatran etexilate capsules

  • Experimental
    Dabigatran etexilate capsules and quinidine sulfate tablets

    Drug: Dabigatran etexilate capsules · Drug: Quinidine sulfate tablets

  • Active comparator
    Fexofenadine tablets

    Drug: Fexofenadine tablets

  • Experimental
    Fexofenadine and quinidine sulfate tablets

    Drug: Quinidine sulfate tablets · Drug: Fexofenadine tablets

06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration-time curve of dabigatran in plasma at steady state over one dosing interval)

    Time frame: Before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00 and 12:00 hours after dosing on day 3

  2. Cmax,ss (maximum concentration of dabigatran in plasma at steady state)

    Time frame: Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3

  3. AUC0-∞ (area under the concentration-time curve of fexofenadine in plasma over the time interval from 0 to infinity)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

  4. Cmax (maximum measured concentration of fexofenadine in plasma)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

Secondary outcomes

  1. AUC0-tz,ss (area under the concentration-time curve of dabigatran in plasma from the time point 0 after the last dose at steady state to the last quantifiable dabigatran plasma concentration within the uniform dosing interval τ)

    Time frame: 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24 and 48 hours after dosing on day 3

  2. tz,ss (time of last measurable concentration of dabigatran in plasma within the dosing interval τ at steady state)

    Time frame: 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24 and 48 hours after dosing on day 3

  3. tmax,ss (time from last dosing to the maximum concentration of dabigatran in plasma at steady state)

    Time frame: 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24 and 48 hours after dosing on day 3

  4. CL/Fss (apparent clearance of dabigatran in the plasma at steady state)

    Time frame: Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3

  5. Cmin,ss (minimum measured concentration of dabigatran in plasma at steady state)

    Time frame: Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3

  6. Cavg (average concentration of dabigatran at steady state)

    Time frame: Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3

  7. C10,2 (total dabigatran concentration 10 hours after the second dabigatran etexilate administration)

    Time frame: Day 2, 22 hours after the first dose on day 1

  8. tmin,ss (time from last dosing to the minimum concentration of dabigatran in plasma at steady state over a uniform dosing interval τ)

    Time frame: Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3

  9. MRTpo,ss (mean residence time of dabigatran in the body at steady state after oral administration)

    Time frame: Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3

  10. Vz/Fss (apparent volume of distribution of dabigatran during the terminal phase λz at steady state following an extravascular administration)

    Time frame: Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3

  11. Cmax (maximum measured concentration of quinidine in plasma)

    Time frame: Pre-dose, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00, 11:00, 13:00, 25:00 and 49 hours after dosing

  12. AUC0-∞ (area under the concentration-time curve of quinidine in plasma over the time interval from 0 to infinity)

    Time frame: Pre-dose, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00, 11:00, 13:00, 25:00 and 49 hours after dosing

  13. AUC0-tz (area under the concentration-time curve of fexofenadine in plasma from the time point 0 after the last dose to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

  14. tmax (time from last dosing to the maximum measured concentration of fexofenadine in plasma)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

  15. t½ (terminal half-life of fexofenadine in plasma)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

  16. MRTpo (mean residence time of fexofenadine in the body after p.o. administration)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

  17. CL/F (apparent clearance of fexofenadine in plasma following extravascular administration)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

  18. Vz/F (apparent volume of distribution of fexofenadine during the terminal phase λz following an extravascular dose)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1

  19. t½ (terminal half-life of dabigatran in plasma at steady state)

    Time frame: Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 3

  20. Cpre,ss (pre-dose concentration of dabigatran in plasma immediately before administration of the following dose at steady state)

    Time frame: Before dose on day 3, day 4, and day 5

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007 and a primary completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Nov 2007
Primary completionActual
Jan 2008
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171546
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Nov 2007
Primary completion
Jan 2008
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Quinidine · Fexofenadine

Start the discussion